Viridian Therapeutics: Cautious Optimism As Key Milestones Approach (Rating Downgrade) [Seeking Alpha]
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: Seeking Alpha
VRDN focuses on developing treatments for thyroid eye disease, and analyst firms project huge revenue and earnings growth in the coming years. The company has smartly addressed its long-term funding needs in recent months in anticipation of a coming marketing rollout upon FDA approval. An updated analysis around Viridian Therapeutics follows in the paragraphs below. Looking for a helping hand in the market? Members of The Biotech Forum get exclusive ideas and guidance to navigate any climate. Learn More » Torsten Asmus/iStock via Getty Images Today, I am putting Viridian Therapeutics, Inc. ( VRDN in the spotlight for the first time since my article on this promising biopharma concern in early June of last year. The stock has experienced a nice rally since then. The last More on my IG service Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of att
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Hot Picks: Biotech rebound turns to rare disease catalysts [BNN Bloomberg (Canada)]BNN Bloomberg
- Viridian Therapeutics (NASDAQ:VRDN) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $42.00 price target on the stock.MarketBeat
- Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by analysts at Wells Fargo & Company from $26.00 to $29.00. They now have an "equal weight" rating on the stock.MarketBeat
- Viridian Therapeutics (NASDAQ:VRDN) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Viridian Therapeutics (NASDAQ:VRDN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.MarketBeat
VRDN
Earnings
- 2/27/25 - Beat
VRDN
Sec Filings
- 1/2/26 - Form 4
- 12/31/25 - Form 144
- 11/14/25 - Form SCHEDULE
- VRDN's page on the SEC website